ClinicalTrials.gg
RecruitingNCT05675332Updated Jun 25, 2026

Effects of Stereotype Threat on Impulsivity and Its Relation to Alcohol Use in African Americans: An fMRI Study

An interventional study of Task-based behavioral intervention and Task-based behavioral intervention in Alcohol Drinking, sponsored by Icahn School of Medicine at Mount Sinai. Recruiting at 1 site in United States. Open to participants aged 21 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
21 Years to 35 Years
Sex
All
01

Study summary

The purpose of this study is to investigate the behavioral and neural correlates of stress exposure. Results from this study will enrich the understanding of how sociocultural, behavioral, and neural factors combine to influence alcohol use.

02

Conditions studied

  • Alcohol Drinking

Browse trials for

03

In context

Alcohol Drinking

701 studies on the registry are indexed under Alcohol Drinking; 133 are open to participants now.

This study's planned enrollment of 280 is above the median of 122 across 607 interventional studies indexed under Alcohol Drinking.

Browse Alcohol Drinking studies →

Lead sponsor

Icahn School of Medicine at Mount Sinai is the lead sponsor of 776 studies on the registry; 176 are open to participants now.

Of its 125 completed or terminated interventional studies of FDA-regulated products, 83 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 21 and 35 years of age (inclusive);
  • Fluent in English;
  • Right-handed

Exclusion criteria

Exclusion Criteria:

  • Younger than 21 years of age;
  • Left-handed
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
280 participants (estimated)

Study arms

  • Placebo comparator
    no stress exposure

    no threat stress

    Behavioral: Task-based behavioral intervention

  • Active comparator
    stress exposure

    exposure to stress threat

    Behavioral: Task-based behavioral intervention

Interventions

  • BehavioralTask-based behavioral intervention

    Brief behavioral intervention is absent of stressors.

  • BehavioralTask-based behavioral intervention

    Brief behavioral intervention involves interacting with common everyday types of stress.

06

What researchers measure

Primary outcomes

  1. Blood oxygen-level dependent (BOLD) signal

    Blood oxygen-level dependent (BOLD) signal in brain regions of interest (ROI) measured using fMRI

    Time frame: Baseline

  2. Resting-state functional connectivity in brain regions

    Resting-state functional connectivity - brain activity measured using fMRI

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
    Recruiting
    • Uraina Clark, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — There is no plan to share IPD

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05675332
Responsible party
Uraina S Clark (Associate Professor, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Jan 9, 2023
Start date
Dec 9, 2022
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Jun 25, 2026

Study contacts

Shivani Doshi
Contact
shivani.doshi@mssm.edu
212-241-6582
Uraina Clark, PhD
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion